Toan C. Ong - Concepedia

Author

Toan C. Ong

University of Colorado Anschutz Medical Campus ORCID

Also Known As

, Ong, Toan C, Rebecca Conway, Sue VandeWoude, T. Ong, T.C. Ong, Toan C Ong, Toan C. Ong, Toan Ong, VandeWoude, Sue

114

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Anschutz Medical Campus Kaiser Permanente Intermountain Healthcare University of Colorado Denver HealthPartners

About

Toan C. Ong is an author at University of Colorado Anschutz Medical Campus specializing in public health, medicine, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	528
2	Engineering	4	4	109
3	Education	1	1	28
4	Language Studies	1	1	57
5	Management	1	1	47

Toan C. Ong

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
A Harmonized Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic Health Record Data Michael G. Kahn, Tiffany J. Callahan, Juliana Barnard, eGEMs (Generating Evidence & Methods to improve patient outcomes)	2016	565
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings Mark G. Thompson, Edward Stenehjem, Shaun J. Grannis, New England Journal of Medicine	2021	490
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, MMWR Morbidity and Mortality Weekly Report	2022	466
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 Mark G. Thompson, Karthik Natarajan, Stephanie A. Irving, MMWR Morbidity and Mortality Weekly Report	2022	427
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, BMJ	2022	194
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022 Nicola P. Klein, Melissa S. Stockwell, Maria Demarco, MMWR Morbidity and Mortality Weekly Report	2022	192
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021 Peter J. Embí, Matthew E. Levy, Allison L. Naleway, MMWR Morbidity and Mortality Weekly Report	2021	188
Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021 Shaun J. Grannis, Elizabeth Rowley, Toan C. Ong, MMWR Morbidity and Mortality Weekly Report Sars-cov-2 B.1.617.2Covid-19 EpidemiologyDelta VariantVaccine HesitancyJune–august 2021	2021	156
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 Ruth Link‐Gelles, Matthew E. Levy, Manjusha Gaglani, MMWR Morbidity and Mortality Weekly Report	2022	124
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 Mark W. Tenforde, Zachary A. Weber, Karthik Natarajan, MMWR Morbidity and Mortality Weekly Report	2022	109

Page 1